Filing Flows › Shoulder Innovations (SI) › Guidance & outlook
Shoulder Innovations (SI) guidance and outlook
Shoulder Innovations (SI) raised its guidance on Nov 5, 2026: Revenue $68.0M–$70.0M for FY2026; Revenue +44% to +48% for FY2026. Shoulder Innovations' 10-Q filed Nov 5, 2026 makes 33 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $68.0M–$70.0M | raised |
| Revenue | FY2026 | +44% to +48% | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We expect that future growth in the shoulder surgical care market will be significantly driven by ASCs as hospitals face capacity constraints and are more limited in their ability to meet increasing demand.
- While we believe that the number of implant systems sold is a useful indicator and is helpful in tracking the progress of our current business, we anticipate this metric may be substituted for additional or different metrics as our business continues to grow and scale.
- We believe the following important factors have impacted and will continue to impact our results of operations for the foreseeable future.
- To drive adoption, our commercial organization is strategically focused on surgeons in hospital and ASC settings, and leverages our internal business intelligence platform to appropriately target surgeons in the shoulder surgical care market.
- We intend to continue scaling our commercial organization to further drive awareness, adoption and demand.
- Over time, we expect to further expand and utilize our external network of independent distributors.
- Our financial performance will be significantly impacted by the extent to which we can increase awareness of our ecosystem, as well as the timing and rate of adoption of our implant systems by key stakeholders in the shoulder surgical care market.
- We expect to continue to focus on long-term revenue growth through investments in our ecosystem and expansion of our operations.
- With a new version of ProVoyance now in place, we expect to commence a limited user release of the InSet Clutch guide system in the first quarter of 2027.
- Additionally, we are targeting FDA submission in 2027 for a new concept for reverse procedures, branded InSet One, a patient-matched, additively manufactured iteration of our InSet Reverse solution, purpose-built for our risk-based approach to preoperative planning.
- We anticipate we will continue to invest significantly in product development, including with respect to our supporting technologies, in order to further bolster our ecosystem.
- As we expand our operations in line with our anticipated growth, we will be required to maintain sufficient levels of inventory and instrumentation to meet our estimated demand, which we expect will increase expenses.
Shoulder Innovations' latest quarter
Shoulder Innovations, Q3 2026: revenue $16.2M (+38% year over year), operating margin -46.9%, net loss $7.0M, operating cash flow −$6.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Shoulder Innovations raise or lower its guidance?
Shoulder Innovations (SI) raised its guidance on Nov 5, 2026: Revenue $68.0M–$70.0M for FY2026; Revenue +44% to +48% for FY2026.
What does Shoulder Innovations expect?
We expect that future growth in the shoulder surgical care market will be significantly driven by ASCs as hospitals face capacity constraints and are more limited in their ability to meet increasing demand. While we believe that the number of implant systems sold is a useful indicator and is helpful in tracking the progress of our current business, we anticipate this metric may be substituted for additional or different metrics as our business continues to grow and scale. We believe the following important factors have impacted and will continue to impact our results of operations for the fore
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.